Terry Friedlander
@DrTFriedlander
Followers
236
Following
4
Statuses
15
Professor of Medicine at UCSF, Robert and Virginia O’Reilly Endowed Chair, and Chief, ZSFG Division of Hematology & Oncology
San Francisco, CA
Joined October 2009
1
5
33
Long awaited combination of Sacituzumab plus Immunotherapy in the JCO. Congrats to Dr Grivas @PGrivasMDPhD all the authors.
0
2
8
Great talk today by Kala Sridhar @kalasri3 at #ESMOAsia2023 on the current landscape in bladder cancer. So many new developments in such a short time!
0
2
15
Great start to Uromigos Live meeting. Lots to discuss in frontline mUC space. All star pane here! #UromigosLive 2023
0
5
10
RT @thomashopemd: So excited to to finally see our trial of combining check point inhibitors (pembrolizumab) with a single dose of 177Lu-PS…
0
32
0
RT @koshkin85: Concluding another amazing @PCFnews @PCF_Science retreat with lots of great science and celebration of 2023 class of Young I…
0
9
0
Discussing LITESPARK-005 trial. Some patients getting good responses (22.5% PR, 3.5% CR rates) and durable PFS with #belzutifan in late line, TKI-pretreated pts. @maughanonc @_CurioScience_ #RCC
1
2
10
Latest updates in RCC with my good friend Dr Benjamin Maughan @maughanonc . Exciting data with belzutifan and new TKI / IO combos!#kidneycancer @_CurioScience_ @Huntsman_GU
0
6
16
Listening to a great talk reviewing what’s new in urothelial cancer by my good friend and colleague Dr Petros Grivas @PGrivasMDPhD #curioscience #bladdercancer
0
5
24
Amazing results of EV-302 trial yesterday, significant improvements in OS, PFS, ORR and CR rates. Over half of control arm pts got PD1 therapies, including 30% use of maintenance avelumab, making this an apt really world comparison. #ESMO2023 #bladdercancer #enfortumab
0
6
26
Update on the EV-103 study. Thanks to all the of participants and their families.
0
0
2